Ann: Quarterly Cashflow and Activity Report, page-2

Well they obviously issued it early to also provide an update in relation to COVID-19 so that is a good move IMO.

I like this bit, but I didn't see a lot more than what we already know.

Starpharma is currently finalising arrangements with potential partners prior to commencement of new Targeted (ADC) and non-ADC DEP® programs, following successful meetings at the JP Morgan Healthcare Conference in San Francisco in January.

Vivagel revenues increased again but not by as much as I thought it should have but that is a sign of the times I guess.

And trial preparations cancelled due to COVID-19 but review progress continuing ? Forget about Vivagel BV in the USA until mid 2021 sadly ... what a mess from an indecisive poor management team IMO  !!   As mentioned by many on here - could have done several trials in the almost 1.5 years that has passed since rejection !!

As part of its strategy for FDA approval of VivaGel® BV, Starpharma continues to progress the FDA review process with input from a team of expert FDA consultants (regulatory, statistical, clinical, legal; several ex-FDA) and we are advised that it is possible that COVID-19 activities within the FDA may impact on timing. In view of the COVID-19 pandemic, and in particular, the potential disruption to the US healthcare system, the Company has paused activities relating to a potential BV treatment trial in the US, and this decision also supports Starpharma’s objective to preserve its strong cash position. Starpharma will continue to monitor the situation in the coming months.